John A. Roush Sells 6,561 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

Key Points

• John A. Roush, Director of LeMaitre Vascular, sold 6,561 shares at an average price of $92.55, totaling approximately $607,220, representing a 69.23% decrease in his ownership.
• LeMaitre Vascular recently reported $0.60 earnings per share for the last quarter, exceeding analysts' expectations and marking a 15.0% revenue increase year-over-year.
• The company announced a quarterly dividend of $0.20 per share, indicating an annualized yield of 0.8% and a payout ratio of 38.83%.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the sale, the director directly owned 2,916 shares in the company, valued at approximately $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

LeMaitre Vascular Stock Performance

Shares of LMAT stock traded down $0.87 during midday trading on Monday, hitting $95.04. 120,983 shares of the company were exchanged, compared to its average volume of 189,653. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The firm has a market capitalization of $2.15 billion, a P/E ratio of 46.14, a PEG ratio of 2.47 and a beta of 0.79. The firm's 50 day moving average price is $84.56 and its two-hundred day moving average price is $86.34. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The company had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same quarter last year, the firm earned $0.52 earnings per share. The company's revenue was up 15.0% on a year-over-year basis. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is presently 38.83%.

Institutional Trading of LeMaitre Vascular

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Parkside Financial Bank & Trust increased its holdings in shares of LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 287 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in LeMaitre Vascular during the 1st quarter worth $26,000. NBC Securities Inc. acquired a new position in LeMaitre Vascular in the 1st quarter worth about $36,000. Geneos Wealth Management Inc. increased its holdings in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC bought a new position in LeMaitre Vascular in the second quarter valued at about $47,000. Institutional investors own 84.64% of the company's stock.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several recent research reports. Cantor Fitzgerald boosted their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a research note on Wednesday, August 6th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $98.00.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.